{"pmid":32347144,"title":"Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors.","text":["Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors.","Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal pandemic since the Spanish flu of 1918.(1, 2) COVID-19 may preferentially infect individuals with cardiovascular conditions, is more severe in subjects with cardiovascular comorbidities, may directly or indirectly affect the heart and may interact with cardiovascular medications.(3) In addition, the widespread effects of the pandemic on the global healthcare system affects the routine and emergency cardiac care for patients who are, may be, or are not infected with COVID-19.","J Am Heart Assoc","Gupta, Ajay K","Jneid, Hani","Addison, Daniel","Ardehali, Hossein","Boehme, Amelia K","Borgaonkar, Sanket","Boulestreau, Romain","Clerkin, Kevin","Delarche, Nicolas","DeVon, Holli A","Grumbach, Isabella M","Gutierrez, Jose","Jones, Daniel A","Kapil, Vikas","Maniero, Carmela","Mentias, Amgad","Miller, Pamela S","May Ng, Sher","Parekh, Jai D","Sanchez, Reynaldo H","Teodor Sawicki, Konrad","S J M Te Riele, Anneline","Ann Remme, Carol","London, Barry","32347144"],"abstract":["Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal pandemic since the Spanish flu of 1918.(1, 2) COVID-19 may preferentially infect individuals with cardiovascular conditions, is more severe in subjects with cardiovascular comorbidities, may directly or indirectly affect the heart and may interact with cardiovascular medications.(3) In addition, the widespread effects of the pandemic on the global healthcare system affects the routine and emergency cardiac care for patients who are, may be, or are not infected with COVID-19."],"journal":"J Am Heart Assoc","authors":["Gupta, Ajay K","Jneid, Hani","Addison, Daniel","Ardehali, Hossein","Boehme, Amelia K","Borgaonkar, Sanket","Boulestreau, Romain","Clerkin, Kevin","Delarche, Nicolas","DeVon, Holli A","Grumbach, Isabella M","Gutierrez, Jose","Jones, Daniel A","Kapil, Vikas","Maniero, Carmela","Mentias, Amgad","Miller, Pamela S","May Ng, Sher","Parekh, Jai D","Sanchez, Reynaldo H","Teodor Sawicki, Konrad","S J M Te Riele, Anneline","Ann Remme, Carol","London, Barry"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347144","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1161/JAHA.120.017013","keywords":["covid-19","cardiovascular disease","coronavirus disease 2019","sars-cov-2","cardiovascular risk factors","management","treatment"],"locations":["Spanish"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1665441658213236736,"score":8.599203,"similar":[{"pmid":32219363,"title":"Potential Effects of Coronaviruses on the Cardiovascular System: A Review.","text":["Potential Effects of Coronaviruses on the Cardiovascular System: A Review.","Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level. Coronaviruses are known to affect the cardiovascular system. We review the basics of coronaviruses, with a focus on COVID-19, along with their effects on the cardiovascular system. Observations: Coronavirus disease 2019 can cause a viral pneumonia with additional extrapulmonary manifestations and complications. A large proportion of patients have underlying cardiovascular disease and/or cardiac risk factors. Factors associated with mortality include male sex, advanced age, and presence of comorbidities including hypertension, diabetes mellitus, cardiovascular diseases, and cerebrovascular diseases. Acute cardiac injury determined by elevated high-sensitivity troponin levels is commonly observed in severe cases and is strongly associated with mortality. Acute respiratory distress syndrome is also strongly associated with mortality. Conclusions and Relevance: Coronavirus disease 2019 is associated with a high inflammatory burden that can induce vascular inflammation, myocarditis, and cardiac arrhythmias. Extensive efforts are underway to find specific vaccines and antivirals against SARS-CoV-2. Meanwhile, cardiovascular risk factors and conditions should be judiciously controlled per evidence-based guidelines.","JAMA Cardiol","Madjid, Mohammad","Safavi-Naeini, Payam","Solomon, Scott D","Vardeny, Orly","32219363"],"abstract":["Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level. Coronaviruses are known to affect the cardiovascular system. We review the basics of coronaviruses, with a focus on COVID-19, along with their effects on the cardiovascular system. Observations: Coronavirus disease 2019 can cause a viral pneumonia with additional extrapulmonary manifestations and complications. A large proportion of patients have underlying cardiovascular disease and/or cardiac risk factors. Factors associated with mortality include male sex, advanced age, and presence of comorbidities including hypertension, diabetes mellitus, cardiovascular diseases, and cerebrovascular diseases. Acute cardiac injury determined by elevated high-sensitivity troponin levels is commonly observed in severe cases and is strongly associated with mortality. Acute respiratory distress syndrome is also strongly associated with mortality. Conclusions and Relevance: Coronavirus disease 2019 is associated with a high inflammatory burden that can induce vascular inflammation, myocarditis, and cardiac arrhythmias. Extensive efforts are underway to find specific vaccines and antivirals against SARS-CoV-2. Meanwhile, cardiovascular risk factors and conditions should be judiciously controlled per evidence-based guidelines."],"journal":"JAMA Cardiol","authors":["Madjid, Mohammad","Safavi-Naeini, Payam","Solomon, Scott D","Vardeny, Orly"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219363","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jamacardio.2020.1286","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664638742977052672,"score":260.34216},{"pmid":32248966,"title":"The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.","text":["The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.","Coronavirus disease 2019 (COVID-19), caused by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in a cluster of patients presenting with pneumonia symptoms in Wuhan, China, in December of 2019. Over the past few months, COVID-19 has developed into a worldwide pandemic, with over 400,000 documented cases globally as of March 24, 2020. The SARS-CoV-2 virus is most likely of zoonotic origin, but has been shown to have effective human-to-human transmission. COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, cardiac injury, and death. Given the novel nature of COVID-19, no established treatment beyond supportive care exists currently, but extensive public-health measures to reduce person-to-person transmission of COVID-19 have been implemented globally to curb the spread of disease, reduce the burden on healthcare systems, and protect vulnerable populations, including the elderly and those with underlying medical comorbidities. Since this is an emerging infectious disease, there is, as of yet, limited data on the effects of this infection on patients with cardiovascular disease, particularly so for those with congenital heart disease. We summarize herewith the early experience with COVID-19 and consider the potential applicability to and implications for patients with cardiovascular disease in general and congenital heart disease in particular.","Int J Cardiol","Tan, Weiyi","Aboulhosn, Jamil","32248966"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in a cluster of patients presenting with pneumonia symptoms in Wuhan, China, in December of 2019. Over the past few months, COVID-19 has developed into a worldwide pandemic, with over 400,000 documented cases globally as of March 24, 2020. The SARS-CoV-2 virus is most likely of zoonotic origin, but has been shown to have effective human-to-human transmission. COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, cardiac injury, and death. Given the novel nature of COVID-19, no established treatment beyond supportive care exists currently, but extensive public-health measures to reduce person-to-person transmission of COVID-19 have been implemented globally to curb the spread of disease, reduce the burden on healthcare systems, and protect vulnerable populations, including the elderly and those with underlying medical comorbidities. Since this is an emerging infectious disease, there is, as of yet, limited data on the effects of this infection on patients with cardiovascular disease, particularly so for those with congenital heart disease. We summarize herewith the early experience with COVID-19 and consider the potential applicability to and implications for patients with cardiovascular disease in general and congenital heart disease in particular."],"journal":"Int J Cardiol","authors":["Tan, Weiyi","Aboulhosn, Jamil"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32248966","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijcard.2020.03.063","source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Prevention","Treatment"],"weight":1,"_version_":1663352136199569409,"score":249.88843},{"pmid":32317203,"title":"Cardiovascular complications in COVID-19.","text":["Cardiovascular complications in COVID-19.","BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.","Am J Emerg Med","Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael","32317203"],"abstract":["BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19."],"journal":"Am J Emerg Med","authors":["Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317203","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajem.2020.04.048","keywords":["acute myocardial infarction","covid-19","cardiovascular","dysrhythmia","heart failure","infectious disease","myocarditis","troponin"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087672623104,"score":232.38873},{"pmid":32161990,"pmcid":"PMC7087935","title":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.","text":["Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.","BACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19. METHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies. RESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. CONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart.","Clin Res Cardiol","Li, Bo","Yang, Jing","Zhao, Faming","Zhi, Lili","Wang, Xiqian","Liu, Lin","Bi, Zhaohui","Zhao, Yunhe","32161990"],"abstract":["BACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19. METHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies. RESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. CONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart."],"journal":"Clin Res Cardiol","authors":["Li, Bo","Yang, Jing","Zhao, Faming","Zhi, Lili","Wang, Xiqian","Liu, Lin","Bi, Zhaohui","Zhao, Yunhe"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32161990","week":"202011|Mar 09 - Mar 15","doi":"10.1007/s00392-020-01626-9","keywords":["2019-ncov","covid-19","cardiac injury","cardiovascular metabolic diseases"],"source":"PubMed","topics":["Mechanism","Diagnosis"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874785538048,"score":226.68716},{"pmid":32274570,"pmcid":"PMC7144545","title":"COVID-19 in the heart and the lungs: could we \"Notch\" the inflammatory storm?","text":["COVID-19 in the heart and the lungs: could we \"Notch\" the inflammatory storm?","From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease.","Basic Res Cardiol","Rizzo, Paola","Vieceli Dalla Sega, Francesco","Fortini, Francesca","Marracino, Luisa","Rapezzi, Claudio","Ferrari, Roberto","32274570"],"abstract":["From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease."],"journal":"Basic Res Cardiol","authors":["Rizzo, Paola","Vieceli Dalla Sega, Francesco","Fortini, Francesca","Marracino, Luisa","Rapezzi, Claudio","Ferrari, Roberto"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274570","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s00395-020-0791-5","keywords":["adam17","angiotensin-converting enzyme 2","covid-19","cardiovascular disease","coronavirus disease","furin","notch"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637190064308225,"score":221.5716}]}